Literature DB >> 30190826

Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?

James S Wilmott1,2,1,2, Peter Hersey1,2,1,2, Georgina V Long1,2,1,2, Richard A Scolyer1,2,3,1,2,3.   

Abstract

Entities:  

Keywords:  BRAF; PD1; chemokine; immune response; immunotherapy; melanoma; targeted therapy; tumor infiltrating lymphocytes; tumor microenvironment

Year:  2015        PMID： 30190826      PMCID： PMC6094588          DOI： 10.2217/mmt.14.26

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  19 in total

1.  Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Authors:  Alexander M Menzies; Lauren E Haydu; Lydia Visintin; Matteo S Carlino; Julie R Howle; John F Thompson; Richard F Kefford; Richard A Scolyer; Georgina V Long
Journal:  Clin Cancer Res       Date:  2012-04-24       Impact factor: 12.531

2.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

3.  Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.

Authors:  Allison Ackerman; Oliver Klein; David F McDermott; Wei Wang; Nageatte Ibrahim; Donald P Lawrence; Anasuya Gunturi; Keith T Flaherty; F Stephen Hodi; Richard Kefford; Alexander M Menzies; Michael B Atkins; Georgina V Long; Ryan J Sullivan
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

4.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

5.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

6.  Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Authors:  Antoni Ribas; Rene Gonzalez; Anna Pavlick; Omid Hamid; Thomas F Gajewski; Adil Daud; Lawrence Flaherty; Theodore Logan; Bartosz Chmielowski; Karl Lewis; Damien Kee; Peter Boasberg; Ming Yin; Iris Chan; Luna Musib; Nicholas Choong; Igor Puzanov; Grant A McArthur
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

7.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

8.  Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

Authors:  Paolo A Ascierto; Ester Simeone; Diana Giannarelli; Antonio M Grimaldi; Anna Romano; Nicola Mozzillo
Journal:  J Transl Med       Date:  2012-05-28       Impact factor: 5.531

9.  The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.

Authors:  Hidetoshi Sumimoto; Fumie Imabayashi; Tomoko Iwata; Yutaka Kawakami
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307

10.  Combined targeted therapy and immunotherapy in the treatment of advanced melanoma.

Authors:  James S Wilmott; Richard A Scolyer; Georgina V Long; Peter Hersey
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.